Intellia Therapeutics Inc - Asset Resilience Ratio
Intellia Therapeutics Inc (NTLA) has an Asset Resilience Ratio of 34.96% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Intellia Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Intellia Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NTLA asset base.
Liquid Assets Composition Over Time
This chart breaks down Intellia Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Intellia Therapeutics Inc (NTLA) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $294.42 Million | 34.96% |
| Total Liquid Assets | $294.42 Million | 34.96% |
Asset Resilience Insights
- Very High Liquidity: Intellia Therapeutics Inc maintains exceptional liquid asset reserves at 34.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Intellia Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Intellia Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Intellia Therapeutics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Intellia Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.96% | $294.42 Million | $842.13 Million | +0.34pp |
| 2024-12-31 | 34.62% | $412.33 Million | $1.19 Billion | -18.07pp |
| 2023-12-31 | 52.69% | $685.48 Million | $1.30 Billion | +8.67pp |
| 2022-12-31 | 44.02% | $669.12 Million | $1.52 Billion | -4.29pp |
| 2021-12-31 | 48.30% | $625.28 Million | $1.29 Billion | -16.36pp |
| 2020-12-31 | 64.67% | $437.35 Million | $676.32 Million | -1.89pp |
| 2019-12-31 | 66.56% | $222.50 Million | $334.28 Million | -6.92pp |
| 2018-12-31 | 73.48% | $255.20 Million | $347.31 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $376.24 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $298.97 Million | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more